18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversità Vita-Salute San Raffaele

About this trial

Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.

Eligibility criteria

Qualifiers

Female patients, age>= 18 yrs, diagnosed with primary or advanced breast cancer

LumA or ER-positive Lobular subtypes

candidates to surgery as first treatment regardless of cN

ER-positive Her2 negative BC with ki67>10%

Disqualifiers

ER-negative tumors

Pregnancy;

Contraindication to PET;

Contraindication to MRI;

Trial design

Treatments tested in this trial

  • FES
  • PET/MRI A
  • Translational analysis

Treatment groups

119 Participants
are divided into 1 treatment group

Sponsors and collaborators

Università Vita-Salute San Raffaele

Lead sponsor

IRCCS San Raffaele

Sponsor institution

IRCCS San Raffaele

Collaborator